The Therapeutic Effect of Different Proton Pump Inhibitors on Hp Infected Gastric Ulcers and Their Impact on Interleukin-33 and miR-26a Levels

Abstract

Abstract: Objective To explore the therapeutic effect of different proton pump inhibitors on Helicobacter pylori (Hp) infected gastric ulcers and their impact on interleukin-33 and miR-26a levels. Methods A study was conducted on 86 patients with Hp infected gastric ulcers admitted to the People's Hospital of Lintong District, Xi'an City from June 2022 to June 2023. Divide into two groups using the random number table method, with 43 cases in each group. The control group was given a proton pump inhibitor (omeprazole enteric coated tablets)+colloidal pectin bismuth capsules+clarithromycin tablets+metronidazole tablets quadruple treatment plan, while the observation group was given a proton pump inhibitor (esomeprazole magnesium)+colloidal pectin bismuth capsules+clarithromycin tablets+metronidazole tablets quadruple treatment plan. Compare the total effective rate, Hp eradication rate, the levels of interleukin-33, miR-26a, CD4⁺, CD8⁺, CD4⁺/CD8⁺ between two groups. Results The total therapeutic effect of the observation group was higher than that of the control group, with statistical significance (P<0.05); The Hp eradication rate in the observation group was higher than that of the control group, with statistical significance (P<0.05). After treatment, the levels of IL-33 in both groups were significantly reduced, while the levels of miR-26a were significantly increased. The level of IL-33 s in the observation group was lower than that in the control group, while the level of miR-26a was higher than that in the control group (P<0.05). After treatment, the levels of CD4⁺ and CD8⁺ in both groups showed significant improvement, with the former showing an increase and the latter showing a decrease. The level of CD4⁺ and the ratio of CD4⁺/CD8⁺ in the observation group were higher than those in the control group, while the level of CD8⁺ was lower than those in the control group (P<0.05). Conclusion Compared to omeprazole enteric coated tablets, esomeprazole magnesium can improve clinical treatment efficacy and Hp eradication rate in patients, reduce the level of interleukin-33, increase the level of miR-26a, and improve immune function.

Key words: proton pump inhibitors, Hp infection, gastric ulcer, interleukin-33, MiR-26a

CLC Number:

R573.1

GUO Lan-xin, LIU Yi-fang. The Therapeutic Effect of Different Proton Pump Inhibitors on Hp Infected Gastric Ulcers and Their Impact on Interleukin-33 and miR-26a Levels[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(21): 53-56.

References

[1] 聂颖. 自拟清胃疏肝方联合西医常规治疗胃溃疡伴Hp感染的疗效观察及对血清EGF、PGE2水平的影响[J].中国中医药科技,2022,29(6):942-946.
[2] 袁浩壬,付晓林.Hp感染性胃溃疡患者血清炎症因子、MMP-9和TIMP-1水平变化及其与炎性活动度的相关性[J].海南医学,2022,33(8):968-971.
[3] 蔡晓鹤,丁淑婷,叶方益,等.抗幽愈疡汤联合四联疗法治疗Hp相关性胃溃疡的疗效观察[J].中国中医药科技,2022,29(3):438-440.
[4] 陈朝聪,蔡水苗,刘海珊.质子泵抑制剂联合抗生素治疗对Hp阳性慢性萎缩性胃炎患者血清胃泌素SIL-2R CRP水平及免疫功能的影响[J].河北医学,2020,26(3):429-432.
[5] 李彩玲,宋志强,索宝军,等.质子泵抑制剂和阿莫西林双联方案在幽门螺杆菌感染根除治疗中的应用[J].中华医学杂志,2021,101(10):746-749.
[6] 中华消化杂志编委会.消化性溃疡诊断与治疗规范(2016年,西安)[J].中华消化杂志,2016,36(8):508-513.
[7] 国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:215-216.
[8] 赵静,斯望春,王佩珠,等.幽门螺杆菌阳性胃溃疡患者T淋巴细胞及相关炎症因子水平[J].中华医院感染学杂志,2022,32(7):1014-1017.
[11] 郑秀金,肖佛义,杨卫远.胃得安胶囊联合四联疗法对胃溃疡伴Hp感染患者疗效及血清学指标的影响[J].中国中西医结合消化杂志,2021,29(1):32-35.
[12] 刘婷莉,郭元彪,邓艺,等. Hp感染性胃溃疡患者炎症活动度与血清TNF-α、IL-17表达水平的相关性[J].热带医学杂志,2021,21(9):1154-1157.
[14] 兰春慧. 高剂量质子泵抑制剂-阿莫西林双联方案在幽门螺杆菌根除治疗中的研究进展[J].中国实用内科杂志,2023,43(4):272-276.
[15] 戴书陈,何镔,陆玲玲.何氏胃疡方联合质子泵抑制剂治疗胃溃疡的效果及对炎性因子、胃黏膜屏障功能的影响[J].解放军医药杂志,2022,34(10):89-93,104.
[16] 涂宏飞,张斌,李莉,等.血清IL-32、IL-33、IL-35在不同亚型Hp感染者及胃癌患者中的水平及意义[J].免疫学杂志,2021,37(4):357-362.
[17] 朱秀云,徐晓辉,段磊,等.体检人群幽门螺杆菌感染现状及与糖脂代谢、胃肠激素、miR-26a水平的关联性分析[J].重庆医学,2022,51(3):418-422,427.
[18] 詹士宝,曹正龙.不同质子泵抑制剂四联疗法治疗幽门螺杆菌Hp相关性消化性溃疡的临床疗效比较[J].中国急救复苏与灾害医学杂志,2020,15(z1):59-60,79.
[19] 杨晓茹. 不同质子泵抑制剂联合克拉霉素、阿莫西林治疗消化性溃疡伴Hp感染的效果及安全性对比[J].当代医药论丛,2020,18(17):155-156.
[20] 海花,乌仁图雅,陈金金.“四联”疗法后延长质子泵抑制剂和铋剂治疗对幽门螺杆菌阳性胃溃疡的疗效及安全性分析[J].现代消化及介入诊疗,2020,25(11):1495-1497.